ReviewReviews in cardiovascular medicine2026
The Role of Stress Granules in Cardiovascular Diseases.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research has highlighted the pivotal role of RNA metabolism-related stress responses in the pathophysiology of cardiovascular diseases, particularly atherosclerosis, stroke, atrial fibrillation (AF), and heart failure (HF). Stress granules (SGs) are dynamic, membraneless organelles that arise during RNA metabolism via liquid-liquid phase separation (LLPS), in which mRNA associates with RNA-binding proteins (RBPs). SGs form following translation arrest in response to various external stimuli, resulting in cytoplasmic accumulation of mRNA and RBPs, which subsequently aggregate into membraneless messenger ribonucleoprotein (mRNP) granules, including Cajal bodies, SGs, P bodies, RNA transport granules, and germinal bodies. This review focuses specifically on SGs. SG formation is typically a transient and protective cellular response to stress; however, the dysregulation or persistence of SG formation has been implicated in a range of diseases, including cardiovascular conditions, neurodegenerative disorders, cancers, immune responses, and viral infections. Thus, this review examines the physiology and pathology of SGs, detailing the associated formation, composition, regulation, and function, with a particular focus on the involvement of SGs in cardiovascular diseases (CVDs) and potential therapeutic strategies targeting SGs. Moreover, this review outlines the complete life cycle of SGs and the associated implications in CVD. SGs originate near the endoplasmic reticulum (ER) and mitigate apoptosis by curbing mitochondrial production of reactive oxygen species. SGs can also disrupt the trafficking of specific cargo from the ER to the Golgi apparatus. Furthermore, SGs can repair damaged lysosomes and eventually undergo self-clearance via the autophagy-lysosome pathway. This model provides new perspectives for researchers in cardiovascular medicine, physicians, and translational medical researchers, and may advance our understanding of SG-related pathophysiology and facilitate the identification of novel therapeutic targets for CVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.